![FDA greenlights targeted therapy for lung cancer mutation](https://static.foxnews.com/foxnews.com/content/uploads/2021/01/fda_resized_import-alert.jpg)
FDA greenlights targeted therapy for lung cancer mutation
Fox News
The Food and Drug Administration has approved the first drug for a specific mutation causing lung cancer in adult patients who have undergone at least one systemic treatment, such as chemotherapy.
KRAS mutations are blamed for about 25% of non-small cell lung cancers, and KRAS G12C mutations comprise some 13% of mutations in non-small cell lung cancers, per the FDA. "KRAS mutations have long been considered resistant to drug therapy, representing a true unmet need for patients with certain types of cancer," Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research, said in a statement posted Friday. "Today’s approval represents a significant step towards a future where more patients will have a personalized treatment approach."More Related News